Floatz logo

Meperidine

Schizophenia Disorder

Yeongseok YunSmall moleculePhase 4 / ApprovedActive
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Schizophenia Disorder cohort.

Asset / SponsorPhaseRating
Olanzapine-Samidorphan
New York State Psychiatric Institute
Phase 4BBB
ETOMIDATE
Yeongseok Yun
Phase 4BB
Remimazolam
Yeongseok Yun
Phase 4BB
TRIHEXYPHENIDYL
University of Pittsburgh
Phase 4BB

Same molecule, other indications

Meperidine is also rated in:

choledocholithiasisDormant
BBB
Indicative ·
72 / 100
View asset →
pancreatitisDormant
BB
Indicative ·
68 / 100
View asset →
Major Depression DisordersDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →